NCT06169826WithdrawnPhase 4
Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 27 Apr 2025
Reason given: withdrawn by the PI
Brief summary (registry, in English)
Oral supplementation of histidine in patients with cognitive dysfunction should increase brain anserine, carnosine and histamine levels which will result in improved cognition via numerous proven in vivo mechanisms including increasing blood flow, neurogenesis, angiogenesis, activation of histaminergic neural pathways and autophagy of beta-amyloid protein, which is pathognomonic for Alzheimer's disease. Randomized into one of 2 arms to receive Histidine or placebo to take for up to 3 months. Baseline evaluation and followup evaluation at 3 months postop.
- Status (registry)
- Withdrawn
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- First submitted
- 4 Dec 2023
- Start date
- Apr 2025
- Primary completion date
- Apr 2026
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Alzheimer disease
- NCT number
- NCT06169826
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- psychiatric
Who the study is looking for
- >49 years
- Live at home currently
- Clinical Dementia Score of 3.0 or higher
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Atrium Health Wake Forest Baptist | Winston-Salem | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.